Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?

Detalles Bibliográficos
Autores principales: Lemmon, Christopher, Pennell, Nathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578493/
https://www.ncbi.nlm.nih.gov/pubmed/33145076
http://dx.doi.org/10.21037/jtd-20-1817
_version_ 1783598378405330944
author Lemmon, Christopher
Pennell, Nathan A.
author_facet Lemmon, Christopher
Pennell, Nathan A.
author_sort Lemmon, Christopher
collection PubMed
description
format Online
Article
Text
id pubmed-7578493
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-75784932020-11-02 Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? Lemmon, Christopher Pennell, Nathan A. J Thorac Dis Editorial Commentary AME Publishing Company 2020-09 /pmc/articles/PMC7578493/ /pubmed/33145076 http://dx.doi.org/10.21037/jtd-20-1817 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Lemmon, Christopher
Pennell, Nathan A.
Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
title Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
title_full Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
title_fullStr Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
title_full_unstemmed Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
title_short Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
title_sort use of adjuvant egfr tyrosine kinase inhibitors in early stage egfr-mutant non-small cell lung cancer: is the evidence strong enough?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578493/
https://www.ncbi.nlm.nih.gov/pubmed/33145076
http://dx.doi.org/10.21037/jtd-20-1817
work_keys_str_mv AT lemmonchristopher useofadjuvantegfrtyrosinekinaseinhibitorsinearlystageegfrmutantnonsmallcelllungcanceristheevidencestrongenough
AT pennellnathana useofadjuvantegfrtyrosinekinaseinhibitorsinearlystageegfrmutantnonsmallcelllungcanceristheevidencestrongenough

Ejemplares similares